Toronto Dominion Bank
PHAS

Toronto Dominion Bank’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Toronto Dominion Bank’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,670
Closed -$3K – 1796
2022
Q2 		$3K Sell
4,670
-980
-17% -$938 ﹤0.01% 1223
2022
Q1 		$7K Buy
5,650
+600
+12% +$973 ﹤0.01% 1280
2021
Q4 		$13K Buy
+5,050
New +$15.3K ﹤0.01% 1396

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PTP
Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

Toronto Dominion Bank's PHAS Position: Q3 2022 in Review

Toronto Dominion Bank sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 4,670 shares — an estimated $3K sold.

Toronto Dominion Bank first reported a position in PHAS in Q4 2021 and held it in 3 quarters. The position peaked at $13K in Q4 2021. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

  • Toronto Dominion Bank reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 4,670 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $3K.
  • Toronto Dominion Bank first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Toronto Dominion Bank's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $13K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Toronto Dominion Bank's 13F filing for Q3 2022, filed 9 Nov 2022.